Latest Breaking News On - Research association de recherche - Page 1 : comparemela.com

Lynparza approved in China as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer

Lynparza approved in China as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Ding maUnited kingdomDave fredricksonBeihua kongEliav barrInvestigateurs national des etudes cancers ovariensFrench national cancer institute incaEuropean network of gynaecological oncological trialDuring european society for medical oncology congressResearch association de rechercheCompany on twitter astrazenecaMerck co incChina national medical products administrationResearch laboratoriesMember of the chinese academy engineeringHead of global clinical development

AstraZeneca: LYNPARZA (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials

Landmark 5-year follow-up of PAOLA-1 Phase III trial demonstrated LYNPARZA plus bevacizumab meaningfully extended survival with 65.5% of HRD-positive patients surviving 5 years vs. 48.4% treated with

Sao pauloUnited kingdomRhode islandUnited statesIsabelle ray coquardPaul disilvestroJessica mcduellBrendan mcevoyEliav barrSusan galbraithInvestigateurs national des etudes cancers ovariensNational cancer instituteMerck research laboratoriesEuropean network of gynaecological oncological trialEuropean society of medical oncologyResearch association de recherche